ProPhase Labs Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 9.32
Dividend & YieldN/A$ (N/A)
Beta -0.29
Market capitalization 163.75M
Operating cash flow 23.09M
ESG Scores unknown

Company description

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial Ratios
Quick Ratio3.65
Working Capital0.14
Return On Equity0.11
Debt To Equity0.17
Fixed Asset Ratio0.15
Fixed Interest Cover8.54

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -125k -14k 3.34M 5.06M
Total Cashflows From Investing Activities 11.86M 5.54M -1.02M -19.67M
Net Borrowings 10M 10M 10M -45k
Total Cash From Financing Activities -11.36M -5.82M 9.99M 35.13M
Change To Operating Activities -198k -255k -1.44M 270k
Issuance Of Stock 337k 40.63M 40.63M 40.63M
Net Income -1.74M -3.15M -2.12M 6.27M
Change In Cash -1.62M -1.12M 6.38M 1.84M
Effect Of Exchange Rate
Total Cash From Operating Activities -2.12M -841k -2.59M -13.62M
Depreciation 383k 398k 458k 3.56M
Change To Account Receivables -1.02M 936k -1.14M -38.2M
Other Cashflows From Financing Activities 1k -10k -10k
Change To Netincome 956k 796k -414k 11.15M
Capital Expenditures -140k -228k -1.69M -4.23M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 398k 332k 1.08M 9.69M
Income Before Tax -1.47M -3.11M -2.31M 5.3M
Net Income -1.74M -3.15M -2.12M 6.27M
Selling General Administrative 6.02M 5.52M 7.5M 22.49M
Gross Profit 4.78M 2.62M 4.61M 41.99M
Ebit -1.63M -3.24M -3.97M 9.8M
Operating Income -1.63M -3.24M -3.97M 9.8M
Interest Expense -61k -295k -295k -1.15M
Income Tax Expense 103k 12k -968k
Total Revenue 13.13M 9.88M 14.51M 79.04M
Cost Of Revenue 8.35M 7.26M 9.91M 37.05M
Total Other Income ExpenseNet 167k 133k 1.66M -4.5M
Net Income From Continuing Ops -1.57M -3.11M -2.33M 6.27M
Net Income Applicable To Common Shares -1.74M -3.15M -2.12M 6.27M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 4.23M 1.04M 20.85M 30.67M
Total Stockholder Equity 16.5M 11.23M 10.56M 58.63M
Other Current Liabilities 3.33M 180k 468k 3.68M
Total Assets 20.74M 12.27M 31.41M 89.3M
Common Stock 14k 14k 14k 16k
Other Current Assets 4.83M 4.81M 250k
Retained Earnings 4.53M -1.51M -3.63M 2.64M
Treasury Stock -47.51M -47.49M -47.5M -48.58M
Cash 1.55M 434k 6.82M 8.41M
Total Current Liabilities 4.23M 933k 6.29M 15.52M
Other Stockholder Equity -24k -2k -11k -175k
Property, Plant, and Equipment 2.5M 2.33M 8.31M 10.35M
Total Current Assets 18.24M 9.95M 15.89M 61.32M
Net Tangible Assets 16.5M 11.23M 8.42M 42.07M
Net Receivables 2.97M 2.01M 3.15M 37.71M
Accounts Payable 437k 432k 3.77M 7.03M


Insider Transactions

Here are the insider transactions of stock shares related to ProPhase Labs Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
KARKUS TED WILLIAMConversion of Exercise of derivative security at price 0.60 per share.D2022-10-14Chief Executive Officer600k
KARKUS TED WILLIAMConversion of Exercise of derivative security at price 0.60 per share.D2022-08-10Chief Executive Officer600k
KARKUS TED WILLIAMConversion of Exercise of derivative security at price 2.00 per share.D2022-05-23Chief Executive Officer450k
BRADY MONICA LConversion of Exercise of derivative security at price 2.15 - 3.18 per share.D2022-05-23Officer39.25k
BARR JASON MICHAELPurchase at price 6.48 per share.D2022-03-10Director750
BARR JASON MICHAELPurchase at price 6.48 per share.D2022-03-10Director721
KARKUS TED WILLIAMPurchase at price 5.07 per share.D2021-06-03Chief Executive Officer33.94k
KARKUS TED WILLIAMStock Gift at price 0.00 per share.D2021-05-07Chief Executive Officer120k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to ProPhase Labs Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on ProPhase Labs Inc

Here is the result of two systematic investment strategies applied to ProPhase Labs Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on ProPhase Labs Inc

The following chart shows the equity curve of the two systematic investment strategies applied to ProPhase Labs Inc:

ProPhase Labs Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 83.08% on the backtest period.

Performance at glance

Performance

83.08 %

Latent gain

1869.51 $

Invested capital

2250.37 $

Annualized return

20.07 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on ProPhase Labs Inc

This is the result of two momentum investment strategies applied to ProPhase Labs Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on ProPhase Labs Inc

The following chart shows all the entries opened by the momentum investment system on ProPhase Labs Inc:

ProPhase Labs Inc momentum entries
  • The first momentum investment strategy would give 99.08% of return on ProPhase Labs Inc. That represents 5691.17$ of latent gain with 5743.91$ of employed capital.
  • The second momentum investment strategy would give 88.27% of return on ProPhase Labs Inc. That represents 2658.11$ of latent gain with 3011.17$ of employed capital.
Performance at glance (1Q Momentum)

Performance

99.08 %

Latent gain

5691.17 $

Invested capital

5743.91 $

Annualized return

120.43 %
Performance at glance (2Q Momentum)

Performance

88.27 %

Latent gain

2658.11 $

Invested capital

3011.17 $

Annualized return

24.12 %

Momentum equity curve on ProPhase Labs Inc

The following chart shows the equity curve of the two momentum strategies applied to ProPhase Labs Inc:

ProPhase Labs Inc momentum equity

Note: the dividends potentially given by ProPhase Labs Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on ProPhase Labs Inc

The following chart shows the employed capital evolution of the two momentum strategies on ProPhase Labs Inc since the beginning:

ProPhase Labs Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on ProPhase Labs Inc

Buy the dip entry openings on ProPhase Labs Inc

ProPhase Labs Inc

The performance achieved by the robo-advisor on ProPhase Labs Inc is 257.72%. That represents 644.14$ of latent gain with 249.94$ of employed capital. The following chart shows ProPhase Labs Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of ProPhase Labs Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

257.72 %

Latent gain

644.14 $

Invested capital

249.94 $

Annualized return

120.43 %

Equity curve of the strategy applied to ProPhase Labs Inc

The following chart shows the result of the investment strategy applied to ProPhase Labs Inc:

ProPhase Labs Inc

Note: the dividends potentially given by ProPhase Labs Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on ProPhase Labs Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on ProPhase Labs Inc:

ProPhase Labs Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on ProPhase Labs Inc

In this section, I will compare the three previous investment strategies applied to ProPhase Labs Inc.

Equity curve comparison on ProPhase Labs Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

ProPhase Labs Inc investment strategy comparison

Employed capital comparison on ProPhase Labs Inc

ProPhase Labs Inc investment comparison

Performance comparison on ProPhase Labs Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 83.08% 1869.51$ 2250.37$ 20.07%
Momentum 1 quarter 99.08% 5691.17$ 5743.91$ 25.41%
Momentum 2 quarters 88.27% 2658.11$ 3011.17$ 24.12%
Non-directional 257.72% 644.14$ 249.94$ 120.43%
Annualized return comparison

Automatic investment

20.07 %

Momentum 1Q

24.12 %

Momentum 2Q

24.12 %

Non-directional

120.43 %

Correlated stocks

Here are the most positively and negatively correlated stocks with ProPhase Labs Inc:

Positive correlations

Most correlated stocks this year

  • ProPhase Labs Inc

  • Most correlated stocks last 3 months

  • ProPhase Labs Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between ProPhase Labs Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of ProPhase Labs Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name ProPhase Labs Inc
    Country United States
    City Garden City
    Address 711 Stewart Avenue
    Phone 215 345 0919
    Website www.prophaselabs.com
    FullTime employees 129
    Industry Drug Manufacturers—Specialty & Generic
    Sector Healthcare
    Exchange XNAS
    Ticker PRPH
    Market www.nasdaq.com

    ProPhase Labs Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown